U.S. FDA approves Rigel Pharma's treatment for a type of leukemia




  • In Health
  • 2022-12-01 22:19:15Z
  • By Reuters
 

(Reuters) -Rigel Pharmaceuticals said on Thursday the U.S. health regulator has approved its drug for the treatment of patients with a type of leukemia, sending its shares up 14% in extended trading.

The Food and Drug Administration approved the drug, which will be sold under the brand Rezlidhia, for the treatment of a type of cancer of the blood and bone marrow called acute myeloid leukemia in patients with a susceptible genetic mutation.

Approval for the oral drug was supported by data from the company's mid-stage study, which showed a 35% rate for complete remission of the cancer with a complete or partial recovery in blood count.

Rezlidhia will be the company's second treatment to get approval from the FDA after Tavalisse for a rare bleeding disorder called immune thrombocytopenic purpura.

Rigel acquired the drug through a licensing agreement with Forma Therapeutics under which Rigel got the rights to develop, manufacture and commercialize Rezlidhia and the latter received an upfront payment of $2.0 million.

Forma can get an additional $17.5 million in certain near-term regulatory and first commercial sale milestones, as well as another $215.5 million on achievement of certain development and commercial targets.

Rigel said it plans to work with potential partners to further develop and commercialize the product outside the United States.

(Reporting by Leroy Leo in Bengaluru; Editing by Maju Samuel)

COMMENTS

More Related News

'Various safety concerns': Why the FDA declined to regulate CBD as a food or supplement

The FDA's action comes after repeated calls from lawmakers, advocates and consumer groups for CBD to be allowed in foods and supplements.

US to make it easier for gay men to donate blood
US to make it easier for gay men to donate blood

The FDA will soon remove a three month abstinence policy for donations for men who have sex with men.

FDA classifies recall of LivaNova
FDA classifies recall of LivaNova's blood-pumping system controller as most serious
  • US
  • 2023-01-27 18:00:39Z

The medical device company recalled 589 units of the LifeSPARC system's controller, through the period of Dec. 19, 2019 to Nov. 17, 2022, for a software...

FDA eases rules again for gay men seeking to donate blood
FDA eases rules again for gay men seeking to donate blood
  • US
  • 2023-01-27 14:35:51Z

The U.S. is moving to ease restrictions on blood donations from gay and bisexual men and other groups that traditionally face higher risks of HIV. The Food ...

FDA
FDA's advisers back plan to simplify COVID-19 vaccinations
  • World
  • 2023-01-26 23:08:25Z

The U.S. is poised to make COVID-19 vaccinations more like a yearly flu shot, a major shift in strategy despite a long list of questions about how to best...

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

  • 토토사이트
    (2022-12-27 08:12:19Z)

    I visited again after a long time. It still seems like a good blog after a long time. It's been a while since I got refreshed. I hope to see you again next time.

    REPLY

Top News: Health